Is Big Pharma Rushing Another Vaccine to Market?
Novavax, a company that has been struggling to get a foothold in the vaccine world, was poised to make waves with its groundbreaking new COVID-Flu combo vaccine.
But before you roll up your sleeves for another shot, here’s the latest update that’s raising eyebrows.
Recently, the U.S. Food and Drug Administration (FDA) suspended clinical trials for the much-anticipated vaccine after a participant developed worrying symptoms of motor neuropathy—a condition where nerve damage disrupts muscle control.
The vaccine, designed to protect against both COVID and the flu in a single shot, now faces significant delays.
The company has stressed that there’s no concrete evidence linking the vaccine to the nerve damage symptoms, but can we really trust Big Pharma to prioritize patient safety over profits?
This is the same industry that has been criticized for its handling of the COVID vaccine rollout. Many of us already questioned the COVID vaccine’s rapid development, and with the flu vaccine’s notoriously poor track record of efficacy, is Big Pharma just trying to churn out another moneymaker?
Let’s talk about the flu vaccine. For years, the flu shot has been touted as an annual “must,” especially for vulnerable populations.
But if we’re being honest, its efficacy has been shaky at best. In some years, it’s been as low as 10 percent effective, depending on how well they “guessed” the strains circulating that season.
Now, they want to combine this shaky flu vaccine with the COVID shot in one convenient package? Given the flu shot’s underwhelming results, it’s worth asking—are they just doubling down on profits here?
And let’s not forget that troubling motor neuropathy case. Yes, Novavax claims there’s no confirmed link between the participant’s symptoms and the vaccine, but it’s hard not to raise an eyebrow.
After all, we’ve seen time and again how Big Pharma skirts accountability. When billions of dollars are at stake, are they really placing people over profits?
Novavax’s stock plummeted by 20 percent following this news, which makes you wonder—how much of this is about patient safety and how much is about protecting their bottom line?
While we’re not saying this vaccine couldn’t have its place—especially for those in higher-risk groups—it’s essential to stay informed and discuss your options with your doctor.
Vaccines are never one-size-fits-all, and this combined shot is no different.
Whether or not this new vaccine is worth the risk for you or your family is a conversation worth having with a trusted healthcare provider.
To informed choices,
Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team
P.S. Did COVID accidentally cause a new health crisis? Get the details here.
Sources:
MSN. (2024). Msn.com. https://www.msn.com/en-us/health/other/fda-halts-novavax-s-vaccine-trials-after-safety-scare/ar-AA1so9N4?ocid=winp1taskbar&cvid=7ce20e78ed6548ca82b608c77a8541ae&ei=28
Cohen, J. (2017, September 20). Why flu vaccines so often fail. Www.science.org. https://www.science.org/content/article/why-flu-vaccines-so-often-fail
Cohen, J. (2017, September 20). Why flu vaccines so often fail. Www.science.org. https://www.science.org/content/article/why-flu-vaccines-so-often-fail
